Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Ranking of factors in order of importance as reported by survey respondents regarding the difficulty in accessing the lower uterine segment (A), complicated fetal extraction in ces... by María Jesús Cancelo Hidalgo (12154030)

Subjects:

The global disease burden of <i><i>Klebsiella pneumoniae</i></i> associated LRI for both sexes in 204 countries and territories. (a) The number of deaths in 2021; (b) The EAPC of d... by Juanjuan Li (399633)

Subjects:

Map of the northwestern region of Mexico showing the location of the city of Mazatlan (a). by Francisco Flores-de-Santiago (20391063)

Subjects:

PRV UL4 is a promotor of NLRP3 inflammasome activation. by Xiaohua Zhang (350570)

Subjects:

Regions of significance for the simple block slopes on proportion of risky decisions as a function of past-month nonsuicidal self-injury (NSSI) and task. by Brooke H. Nancekivell (19949839)

PRV UL4 is a promotor of NLRP3 inflammasome Activation. by Xiaohua Zhang (350570)

Subjects:

Screening HBV RNaseH inhibitors in HepDES19 cell for effects on capsids and core protein. by Daniel P. Bradley (10306893)

1466 inhibits capsid accumulation independent of HBV replication. by Daniel P. Bradley (10306893)

HBV RNaseH inhibitors effects on capsid accumulation occur independent of HBV DNA synthesis. by Daniel P. Bradley (10306893)

PVS_ratio changes, ΔPVS_ratio, for different radiation doses within each treatment period: 0M–3M(a), 3M–12M(b), and 12M–FollowUp(c). by Ruitian Song (11045127)

Subjects:

PVS_volume changes, ΔPVS_volumes, for various radiation doses within each treatment period: 0M–3M(a), 3M–12M(b), and 12M–FollowUp(c). by Ruitian Song (11045127)

Subjects:

Age-adjusted annual percent changes (APC) in incidence (A), mortality (B), and prevalence (C) rates per 100,000 over 2014–2023 for both sexes and sex-specific. by Ayana Ablayeva (22103708)

Subjects:

Differences among the classes of CAMs. by Daniel P. Bradley (10306893)

“…A representative HPD <b>1466</b>, with a 50% effective concentration against HBV replication of 0.25 µM, decreased capsid and core protein accumulation by 50–90% in HepDES19 and HepG2.2.15 cells. …”

Fig 5 - by Mísia Helena da Silva Ferro (20623666)

Subjects:

Location of (A) South Sudan and (B) study counties (Maridi, Mundri East, Mundri West, Mvolo and Wulu). by Luís-Jorge Amaral (16406704)

Subjects:

Data Sheet 1_Early caffeine therapy decreases bronchopulmonary dysplasia but might increase mortality in preterm infants? a systematic review and meta-analysis.docx by Juan Ma (417126)

Data Sheet 2_Early caffeine therapy decreases bronchopulmonary dysplasia but might increase mortality in preterm infants? a systematic review and meta-analysis.docx by Juan Ma (417126)

Baseline patient characteristics. by Oscar F. C. van den Bosch (22184246)

Subjects: